Is a Correction Looming Ahead for Reata Pharmaceuticals Inc. (RETA)
Reata Pharmaceuticals Inc. (NASDAQ:RETA) went down by -5.63% from its latest closing price compared to the recent 1-year high of $153.41. The company’s stock price has collected 1.27% of gains in the last five trading sessions. Press Release reported 14 hours ago that CNS Pharmaceuticals Receives
Warren Buffett Meyer Colin John Pharmaceuticals Receives Approval Switzerland Ethics Committee Reata Pharmaceuticals Inc It Worth Investing In Reata Pharmaceuticals Inc
Source: newsheater.com